Full details, including potential risk factors, are given in the Press Release, which can be consulted by clicking on the link below
NCX 470, a Nitric Oxide Donating Bimatoprost, Demonstrates Non-inferiority to Latanoprost in Phase 3 Mont Blanc Clinical Trial

March 9, 2023

View Press Release Corporate presentation Contact us
Previous